4 views left Get unlimited views with a free account

Take your business to the next level. Explore the latest trends and actionable insights to inform business strategy and pinpoint opportunities and risks.

Number of ongoing Clinical Trials (for drugs) involving Hypertension by Phase

Industry: Pharmaceuticals
Current: Other Industry Indicators

There are currently 1795 ongoing clinical trials involving Hypertension
Of the 1795 trials,614 trials are in Phase III
Furthermore, 529 trials are in Phase II

Number of ongoing Clinical Trials (for drugs) involving Hypertension by Phase

View as table

The global pharmaceutical industry is steadily developing new drugs for Hypertension, a Cardiovascular condition. The largest number of ongoing clinical trials for Hypertension is conducted in the Asia-Pacific region. North America and Europe are among some of the other prominent regions engaged in Hypertension-related drug trials.

Actelion Pharmaceuticals Ltd: The leading ongoing Hypertension related clinical trial sponsor

Actelion Pharmaceuticals Ltd is the top sponsor for Hypertension-related ongoing clinical trials.

United Therapeutics Corp, Shanghai Jiao Tong University School of Medicine, Bayer AG, and Acceleron Pharma Inc are among other notable clinical trial sponsors involved in Hypertension. A clinical trial sponsor can be a Company, Government, Individual, or Institution.

Marketed Drugs involving Hypertension

Sacubitril and Valsartan (Entresto, Neparvis, Uperio, Azmarda, LCZ696, Vymada), Macitentan (ACT-064992, Opsumit, Zependo) and Selexipag (Uptravi) are among the key marketed drugs involving Hypertension.

Sacubitril and Valsartan (Entresto, Neparvis, Uperio, Azmarda, LCZ696, Vymada) is a fixed dose combination acts as an anti-hypertensive and cardiovascular agent. It functions via Neprilysin (Neutral Endopeptidase 24.11 or Atriopeptidase or Common Acute Lymphocytic Leukemia Antigen or Skin Fibroblast Elastase or Enkephalinase or CD10 or MME or EC 3.4.24.11) Inhibitor; Type 1 Angiotensin II Receptor (AT1AR or AT1BR or Angiotensin II Type 1 Receptor or AGTR1) Antagonist mechanism of action. Sacubitril and Valsartan is formulated as film coated tablets for oral route of administration. Entresto is indicated to reduce the risk of cardiovascular death and hospitalization for heart failure in patients with chronic heart failure and reduced ejection fraction. Sacubitril and Valsartan was first approved in 2015 and is marketed globally in the US, Japan, the UK, China, Germany and France by several prominent pharma giants including Novartis Pharmaceuticals Corp.

Macitentan (ACT-064992, Opsumit, Zependo) is a novel dual endothelin receptor antagonist (ERA). It functions via Endothelin 1 Receptor (Endothelin A Receptor or EDNRA) Antagonist; Endothelin B Receptor (Endothelin Receptor Non-Selective Type or EDNRB) Antagonist mechanism of action. Macitentan is formulated as film coated tablets for the oral route of administration. Macitentan was first approved in 2013 and is marketed globally in the US, the UK, Australia, France and Germany by several prominent pharma giants including Actelion Pharmaceuticals US Inc.